Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Inotiv (NASDAQ: NOTV) entered a Restructuring Support Agreement with its first lien lenders and an ad hoc noteholder group to execute a prepackaged chapter 11 recapitalization in Texas.
The plan targets about $326 million in debt reduction and includes $65 million in new financing ($40 million bridge and $25 million DIP) while maintaining normal operations.
Inotiv (NASDAQ: NOTV) disclosed a cybersecurity incident detected August 5, 2025, with unauthorized access occurring approximately August 5–8, 2025. The company said certain data may have been acquired, including sensitive personal information, and it notified affected individuals, regulators, and U.S. law enforcement.
Inotiv offered complimentary credit monitoring, launched an external investigation, and said it has taken steps to contain the incident and enhance security.
Inotiv (Nasdaq: NOTV) reported Q1 FY2026 results for the quarter ended December 31, 2025. Revenue was $120.9 million, up 0.8% year-over-year. DSA revenue rose 12.0% and DSA net awards grew ~27% year-over-year. Adjusted EBITDA was $1.8 million (1.5% of revenue).
Consolidated net loss was $28.4 million (23.5% of revenue); operating loss widened to $16.3 million. Cash totaled $12.7 million and total debt was $405.8 million. DSA backlog was $145.4 million. Management cited site exits and ongoing site optimization.
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
The company will host a conference call the same day at 8:30 a.m. Eastern Time with domestic and international dial‑in access and a live webcast. An online replay will be available in the Investors section of Inotiv's website.
Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.
The TruVivo® system uses primary human hepatocytes with human-derived feeder cells to build physiologically relevant in vitro models intended to improve translational predictivity. Inotiv said the integration will align preclinical models more closely with human biology and enable expansion of human-relevant tissue models beyond the liver to support clients across a range of diseases.
The companies framed the collaboration as advancing new approach methodologies to accelerate development of safer, more effective therapies.
Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE’s cloud-based AI/ML multi-omics bioinformatics platform into Inotiv’s Discovery & Translational Sciences Division.
The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings.
Inotiv (Nasdaq: NOTV) reported Q4 FY2025 revenue of $138.1M (+5.9% YoY) and FY2025 revenue of $513.0M (+4.5% YoY). Q4 operating loss narrowed to $6.8M and FY operating loss improved to $30.9M (down 64.2% YoY). Adjusted EBITDA was $11.8M (8.5% of revenue) in Q4 and $34.0M (6.6%) for FY2025. DSA revenue grew 15.7% in Q4 and DSA backlog was $138.2M at Sept 30, 2025. The company sold two U.S. properties to repay term loan principal, engaged Perella Weinberg Partners to explore refinancing, and disclosed a August 2025 cybersecurity incident with potential data access under evaluation.
Inotiv (NOTV) ranked 182nd on the 2025 Deloitte Technology Fast 500™ announced Nov. 25, 2025. The company reported 448% revenue growth from fiscal year 2021 to fiscal year 2024, the measurement period for the ranking.
Inotiv said the growth reflects strategic acquisitions, the development of complementary services, and a unified, client-focused CRO model. This is Inotiv’s third consecutive year on the Fast 500 list after prior rankings of 127th (2023) and 138th (2024).
Inotiv (NASDAQ: NOTV) will release fiscal 2025 fourth quarter and full year results for the period ended September 30, 2025 on Wednesday, December 3, 2025 after market close. Management will host a conference call the same day at 4:30 p.m. Eastern Time to discuss results.
Dial-in options include 1-800-225-9448 (Domestic) and 1-203-518-9708 (International) with conference ID INOTIV. A live webcast and an online replay will be available in the Investors section of the company website.
Inotiv (NASDAQ: NOTV) reported preliminary, unaudited Q4 FY2025 revenue of $137.5M–$138.5M and preliminary FY2025 revenue of $512.5M–$513.5M. Management said Discovery and Safety Assessment (DSA) services grew sequentially in Q4 and were up 60% year-over-year. Anticipated DSA backlog was approximately $138.0M at September 30, 2025, with book-to-bill ~1.08x for Q4 and ~1.05x for FY2025. Results are estimates and subject to year-end accounting and audit completion. The company updated its Jefferies Global Healthcare Conference presentation time to 11:00 AM GMT on Nov 18, 2025.